

# Chris Gardiner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3505276/publications.pdf>

Version: 2024-02-01

72  
papers

16,319  
citations

117453

34  
h-index

95083

68  
g-index

77  
all docs

77  
docs citations

77  
times ranked

21967  
citing authors

#	ARTICLE	IF	CITATIONS
1	Automated measurement of coagulation and fibrinolytic activation markers: Outcomes in coronavirus disease 2019 (<scp>COVID</scp>â€19) patients. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 817-822.	0.7	3
2	International Council for Standardization in Haematology (ICSH) laboratory guidance for the evaluation of haemostasis analyserâ€reagent test systems. Part 1: Instrumentâ€specific issues and commonly used coagulation screening tests. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 169-183.	0.7	9
3	International Council for Standardization in Haematology (ICSH) laboratory guidance for the verification of haemostasis analyserâ€reagent test systems. Part 2: Specialist tests and calibrated assays. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 907-916.	0.7	11
4	Plateletâ€enhanced plasma: Characterization of a novel candidate resuscitation fluid's extracellular vesicle content, clotting parameters, and thrombin generation capacity. <i>Transfusion</i> , 2021, 61, 2179-2194.	0.8	7
5	A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CNâ€6500 haemostasis analyser. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1593-1598.	0.7	2
6	A practical method for reducing the interference due to lipaemia in coagulation tests. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 140-144.	0.7	10
7	A comparative evaluation of the CNâ€6000 haemostasis analyser using coagulation, amidolytic, immunoâ€turbidometric and light transmission aggregometry assays. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 643-649.	0.7	5
8	Prevention and treatment of venous thromboembolism in hospital and the community: a research programme including the ExACT RCT. <i>Programme Grants for Applied Research</i> , 2020, 8, 1-104.	0.4	1
9	Considerations towards a roadmap for collection, handling and storage of blood extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1647027.	5.5	96
10	Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology. <i>Molecular Therapy</i> , 2019, 27, 2111-2122.	3.7	120
11	Toward standardization of assays measuring extracellular vesicleâ€associated tissue factor activity. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1261-1264.	1.9	10
12	Tspan18 is a novel regulator of the Ca <sup>2+</sup> channel Orai1 and von Willebrand factor release in endothelial cells. <i>Haematologica</i> , 2019, 104, 1892-1905.	1.7	16
13	Soluble GPVI is elevated in injured patients: shedding is mediated by fibrin activation of GPVI. <i>Blood Advances</i> , 2018, 2, 240-251.	2.5	41
14	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1535750.	5.5	6,961
15	Towards mechanisms and standardization in extracellular vesicle and extracellular RNA studies: results of a worldwide survey. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1535745.	5.5	45
16	Summary of the ISEV workshop on extracellular vesicles as disease biomarkers, held in Birmingham, UK, during December 2017. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1473707.	5.5	60
17	Impact of haemostatic mechanisms on pathophysiology of preeclampsia. <i>Thrombosis Research</i> , 2017, 151, S48-S52.	0.8	21
18	Single particle analysis: Methods for detection of platelet extracellular vesicles in suspension (excluding flow cytometry). <i>Platelets</i> , 2017, 28, 249-255.	1.1	30

#	ARTICLE	IF	CITATIONS
19	Circulating endothelial cell-derived extracellular vesicles mediate the acute phase response and sickness behaviour associated with CNS inflammation. <i>Scientific Reports</i> , 2017, 7, 9574.	1.6	43
20	A performance evaluation of a novel human recombinant tissue factor prothrombin time reagent (Revohem <sup>®</sup> , <sub>PT</sub> ). <i>International Journal of Laboratory Hematology</i> , 2017, 39, 532-538.	0.7	4
21	Updating the MISEV minimal requirements for extracellular vesicle studies: building bridges to reproducibility. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1396823.	5.5	185
22	A Comparison of Different Methodologies for the Measurement of Extracellular Vesicles and Milk-derived Particles in Raw Milk from Cows. <i>Biomarker Insights</i> , 2016, 11, BMI.S38438.	1.0	5
23	The 2nd United Kingdom Extracellular Vesicle Forum Meeting Abstracts. <i>Journal of Extracellular Vesicles</i> , 2016, 5, 30924.	5.5	2
24	Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey. <i>Journal of Extracellular Vesicles</i> , 2016, 5, 32945.	5.5	703
25	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	1.7	67
26	Identification of distinct circulating exosomes in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 353-361.	1.7	111
27	Extracellular vesicles, tissue factor, cancer and thrombosis – discussion themes of the ISEV 2014 Educational Day. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 26901.	5.5	69
28	EVpedia: a community web portal for extracellular vesicles research. <i>Bioinformatics</i> , 2015, 31, 933-939.	1.8	317
29	Pre-eclampsia: The Role of Hemostasis in Its Pathophysiology and Potential Future Therapeutic Options. , 2015, , 159-171.		0
30	Syncytiotrophoblast Vesicles Show Altered micro-RNA and Haemoglobin Content after Ex-vivo Perfusion of Placentas with Haemoglobin to Mimic Preeclampsia. <i>PLoS ONE</i> , 2014, 9, e90020.	1.1	40
31	Obituary. <i>Journal of Extracellular Vesicles</i> , 2014, 3, 23842.	5.5	0
32	Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia. <i>Journal of Neuroinflammation</i> , 2014, 11, 203.	3.1	79
33	Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1182-1192.	1.9	698
34	Microparticle association and heterogeneity of tumor-derived tissue factor in plasma: is it important for coagulation activation?. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 186-196.	1.9	32
35	Brain-derived microvesicles confer sickness behaviours by switching on the acute phase response in the liver. <i>Journal of Neuroimmunology</i> , 2014, 275, 57.	1.1	2
36	Incorporation of Ophiobolin A into Novel Chemoembolization Particles for Cancer Cell Treatment. <i>Pharmaceutical Research</i> , 2014, 31, 2904-2917.	1.7	18

#	ARTICLE	IF	CITATIONS
37	Measurement of refractive index by nanoparticle tracking analysis reveals heterogeneity in extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2014, 3, 25361.	5.5	133
38	Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. <i>Journal of Extracellular Vesicles</i> , 2014, 3, 26913.	5.5	2,110
39	Platelet-Derived Microparticles. , 2013, , 453-467.		10
40	Diagnosis of antiphospholipid syndrome in routine clinical practice. <i>Lupus</i> , 2013, 22, 18-25.	0.8	112
41	Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover. <i>Nucleic Acids Research</i> , 2013, 41, 9500-9513.	6.5	83
42	Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis. <i>Journal of Extracellular Vesicles</i> , 2013, 2, .	5.5	426
43	International Society for Extracellular Vesicles: Second Annual Meeting, 17â€“20 April 2013, Boston, MA (ISEV 2013). <i>Journal of Extracellular Vesicles</i> , 2013, 2, 23070.	5.5	2
44	Characterisation of Syncytiotrophoblast Vesicles in Normal Pregnancy and Pre-Eclampsia: Expression of Flt-1 and Endoglin. <i>PLoS ONE</i> , 2013, 8, e56754.	1.1	157
45	Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. <i>Lancet, The</i> , 2012, 379, 322-334.	6.3	334
46	Exosome-mediated delivery of siRNA in vitro and in vivo. <i>Nature Protocols</i> , 2012, 7, 2112-2126.	5.5	484
47	The clinical significance of differences between point-of-care and laboratory INR methods in over-anticoagulated patients. <i>Thrombosis Research</i> , 2012, 130, 110-114.	0.8	25
48	Invisible vesicles swarm within the iceberg. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 916-918.	1.9	21
49	Review: Does size matter? Placental debris and the pathophysiology of pre-eclampsia. <i>Placenta</i> , 2012, 33, S48-S54.	0.7	232
50	Differential contributions of monocyteâ€•and plateletâ€•derived microparticles towards thrombin generation and fibrin formation and stability. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2251-2261.	1.9	153
51	Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 780-788.	1.7	1,068
52	Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. <i>Neurobiology of Disease</i> , 2011, 42, 360-367.	2.1	612
53	Syncytiotrophoblast Microvesicles Released from Pre-Eclampsia Placentae Exhibit Increased Tissue Factor Activity. <i>PLoS ONE</i> , 2011, 6, e26313.	1.1	69
54	Self-monitoring of oral anticoagulation: does it work outside trial conditions?. <i>Journal of Clinical Pathology</i> , 2009, 62, 168-171.	1.0	18

#	ARTICLE	IF	CITATIONS
55	Point-of-Care Testing in Hemostasis. , 2009, , 72-80.		2
56	Measuring thrombin generation based sensitivity to activated protein C using an automated coagulometer (ACL 9000). International Journal of Laboratory Hematology, 2008, 30, 261-268.	0.7	4
57	Performance Evaluation of a New Small-Volume Coagulation Monitor. American Journal of Clinical Pathology, 2008, 129, 500-504.	0.4	6
58	29 Pregnancy morbidity, tissue factor pathway inhibitor deficiency and resistance to activated protein C. Thrombosis Research, 2007, 119, S104-S105.	0.8	0
59	Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay. Blood Coagulation and Fibrinolysis, 2006, 17, 477-483.	0.5	19
60	Pregnancy loss, tissue factor pathway inhibitor deficiency and resistance to activated protein C. Journal of Thrombosis and Haemostasis, 2006, 4, 2724-2726.	1.9	13
61	A randomised control trial of patient self-management of oral anticoagulation compared with patient self-testing. British Journal of Haematology, 2006, 132, 598-603.	1.2	43
62	Can oral anticoagulation be managed using telemedicine and patient self-testing? A pilot study. International Journal of Laboratory Hematology, 2006, 28, 122-125.	0.2	15
63	Recommendations for Evaluation of Coagulation Analyzers. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2006, 12, 32-38.	1.2	25
64	Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. British Journal of Haematology, 2005, 128, 242-247.	1.2	101
65	An evaluation of rapid D-dimer assays for the exclusion of deep vein thrombosis. British Journal of Haematology, 2005, 128, 842-848.	1.2	42
66	An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation. British Journal of Haematology, 2005, 131, 156-165.	1.2	81
67	Falsely elevated D-dimer results in a healthy patient on account of heterophile antibodies. British Journal of Haematology, 2003, 122, 871-873.	1.2	17
68	An evaluation of screening tests for defects in the protein C pathway: commercial kits lack sensitivity and specificity. Blood Coagulation and Fibrinolysis, 2002, 13, 155-163.	0.5	10
69	The importance of locally derived reference ranges and standardized calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant. British Journal of Haematology, 2000, 111, 1230-1235.	1.2	7
70	The importance of locally derived reference ranges and standardized calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant. British Journal of Haematology, 2000, 111, 1230-1235.	1.2	47
71	Platelet activation responses in vitro to human mast cell activation. British Journal of Haematology, 1999, 106, 208-215.	1.2	4
72	Simultaneous assay of free and total protein S by ELISA using monoclonal and polyclonal antibodies. International Journal of Laboratory Hematology, 1998, 20, 41-45.	0.2	7